BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32833940)

  • 1. Fifty Years of Surgery for Pancreatic Cancer.
    Hackert T; Klaiber U; Pausch T; Mihaljevic AL; Büchler MW
    Pancreas; 2020 Sep; 49(8):1005-1013. PubMed ID: 32833940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study.
    Hackert T; Strobel O; Michalski CW; Mihaljevic AL; Mehrabi A; Müller-Stich B; Berchtold C; Ulrich A; Büchler MW
    HPB (Oxford); 2017 Nov; 19(11):1001-1007. PubMed ID: 28838632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension.
    Bachellier P; Rosso E; Fuchshuber P; Addeo P; David P; Oussoultzoglou E; Lucescu I
    Surgery; 2014 Mar; 155(3):449-56. PubMed ID: 24462078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Group of Pancreatobiliary Surgery in Japan.
    Satoi S; Murakami Y; Motoi F; Sho M; Matsumoto I; Uemura K; Kawai M; Kurata M; Yanagimoto H; Yamamoto T; Mizuma M; Unno M; Kinoshita S; Akahori T; Shinzeki M; Fukumoto T; Hashimoto Y; Hirono S; Yamaue H; Honda G; Kwon M
    Pancreas; 2016 Aug; 45(7):1003-9. PubMed ID: 26692442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
    Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
    Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
    Hartwig W; Gluth A; Hinz U; Koliogiannis D; Strobel O; Hackert T; Werner J; Büchler MW
    Br J Surg; 2016 Nov; 103(12):1683-1694. PubMed ID: 27686238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.
    Chen K; Pan Y; Huang CJ; Chen QL; Zhang RC; Zhang MZ; Wang GY; Wang XF; Mou YP; Yan JF
    BMC Cancer; 2021 Apr; 21(1):382. PubMed ID: 33836678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
    Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
    Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer.
    Karamarković AR; Juloski JT
    Chirurgia (Bucur); 2022 Jun; 117(4):385-398. PubMed ID: 36049095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.